research Disease modifying osteoarthritis drug discovery using a temporal phenotypic reporter in 3D aggregates of primary human chondrocytes
Aromoline and DRD4 are potential targets for osteoarthritis treatment.
Search
for
Sort by
Research
510-540 / 1000+ results
research 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
research 40062 Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: a multicentric study
Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.
research Outcomes of Fat Grafting in the Active Versus Quiescent Phase of Localized Scleroderma
Fat grafting is safe and effective in both active and stable phases of localized scleroderma.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research [Differences in efficacy between drug-eluting beads transbronchial arterial chemoembolization combined with systemic chemotherapy and systemic chemotherapy alone for unresectable lung squamous cell carcinoma].
Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
research Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial
Cinainu is effective and safe for treating children's alopecia areata.
research Monthly versus quarterly dutasteride mesotherapy for male androgenetic alopecia: A randomized trial
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Efficacy of platelet-rich plasma in Asians with androgenetic alopecia: A randomized controlled trial
research Comparison Of Single And Double-Spin Platelet- Rich Plasma Therapy For Treating Androgenetic Alopecia In Males: A Double-Blinded Randomized Controlled Trial
Double-spin PRP is more effective for treating male pattern baldness.
research Dual-phase release finasteride-loaded microspheres for androgenetic alopecia treatment: rapid intervention and sustained control of dihydrotestosterone
A new finasteride treatment may quickly and effectively promote hair regrowth.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research 519 Phase I/IIa clinical trial for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
The gene therapy showed significant wound healing and was safe for treating severe RDEB.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research Treatment of multiple scalp basal cell carcinomas by photodynamic therapy
Photodynamic therapy was effective in treating multiple scalp basal cell carcinomas with minimal side effects and good cosmetic results.
research Efficacy of spironolactone as adjunctive therapy to sodium valproate in bipolar‐I disorder: A double‐blind, randomized, placebo‐controlled clinical trial
Spironolactone improved cognitive performance and early sleep quality but not manic symptoms, appetite, or body weight in bipolar disorder when added to sodium valproate.
research A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia
Latanoprost 0.1% may effectively treat hair loss.
research A randomised open label comparative study of hydroxychloroquine with betamethasone oral minipulse in the management of patients with alopecia areata.
Betamethasone is more effective long-term for alopecia areata than hydroxychloroquine.
research Treatment of Widespread Alopecia Areata in Young Patients with Monthly Oral Corticosteroid Pulse
Monthly oral corticosteroid pulses effectively treat widespread alopecia areata in young patients.
research All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
research Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Photobiomodulation, Photomedicine, and Laser Surgery
Photobiomodulation increased hair count in men with hair loss after 5 weeks, with no further increase after 10 weeks.
research Structure-guided PEGylated fibroblast growth factor 2 variants accelerate wound healing with improved stability
Compound 6 is a promising candidate for better wound healing.
research Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib
Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.
research There are early, gradual and late responders for scalp hair regrowth in patients with alopecia areata treated with baricitinib
Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Therapeutic Burden as Predictor of Response to Baricitinib for Alopecia Areata in Real Life: Prospective Study
Patients with fewer past treatments for alopecia areata respond better to baricitinib.
research 341 ANDROGENETIC ALOPECIA AT VARIOUS AGES AND PROSTATE CANCER RISK IN AN EQUAL ACCESS MULTIETHNIC CASE CONTROL SERIES OF VETERANS
Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.
research Comparison of the efficacy and safety of a picosecond alexandrite laser and a Q-switched alexandrite laser for the treatment of freckles in Chinese patients
Both lasers are equally effective and safe for treating freckles.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.